Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Analysis: Cholesterol-Drug Setback Key To Takeda Pipeline (Japan)

This article was originally published in PharmAsia News

Executive Summary

The setback of Takeda Pharmaceutical's entry into the anti-cholesterol drug market is having a financial impact on Japan's leading drug maker. The company had viewed its TAK-475 as the most promising drug in its pipeline, but the U.S. FDA said it needed more clinical tests before it could approve the drug. Takeda faces 2010 expiration of patents on several of its flagship drugs and needs to come up with substitutes if it is to regain investor confidence. (Click here for more - may require a subscription



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts